RNAseq of 3LL-??RAS lung tumours treated with SHP2 or/and KRAS inhibitors
Intravenous-induced 3LL-?NRAS tumour bearing mice were treated with RMC-4550 or/and RMC-4998 for 7 days and isolated for RNAseq. Overall design: 4 groups of 3LL-?NRAS tumour bearing mice: Vehicle, RMC-4550, RMC-4998, RMC-4550+RMC-4998 treated daily for 7 days. RNA was extracted from isolated  lungs.